Benzinga | Aug 6, 2020 11:38AM EDT

BMO Capital Maintains Outperform on bluebird bio, Lowers Price Target to $108

BMO Capital maintains bluebird bio (NASDAQ:BLUE) with a Outperform and lowers the price target from $112 to $108.